MedMen Enterprises Past Earnings Performance
Past criteria checks 0/6
MedMen Enterprises's earnings have been declining at an average annual rate of -51.2%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 17.4% per year.
Key information
-51.2%
Earnings growth rate
-16.4%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -17.4% |
Return on equity | n/a |
Net Margin | -119.3% |
Last Earnings Update | 25 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How MedMen Enterprises makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
25 Mar 23 | 120 | -143 | 75 | 0 |
24 Dec 22 | 128 | -140 | 84 | 0 |
24 Sep 22 | 134 | -129 | 97 | 0 |
25 Jun 22 | 141 | -150 | 112 | 0 |
26 Mar 22 | 146 | -95 | 124 | 0 |
25 Dec 21 | 142 | -89 | 122 | 0 |
25 Sep 21 | 134 | -118 | 113 | 0 |
26 Jun 21 | 132 | -97 | 110 | 0 |
27 Mar 21 | 126 | -220 | 120 | 0 |
26 Dec 20 | 138 | -221 | 140 | 0 |
26 Sep 20 | 151 | -177 | 174 | 0 |
27 Jun 20 | 155 | -177 | 203 | 0 |
28 Mar 20 | 161 | -44 | 218 | 0 |
28 Dec 19 | 148 | -51 | 241 | 0 |
28 Sep 19 | 138 | -76 | 256 | 0 |
29 Jun 19 | 120 | -68 | 267 | 0 |
30 Mar 19 | 103 | -89 | 280 | 0 |
29 Dec 18 | 86 | -81 | 233 | 0 |
30 Sep 18 | 59 | -75 | 170 | 0 |
30 Jun 18 | 40 | -68 | 105 | 0 |
31 Mar 18 | 21 | -42 | 38 | 0 |
31 Dec 17 | 7 | -28 | 24 | 0 |
30 Sep 17 | 4 | -19 | 16 | 0 |
30 Jun 17 | 3 | -15 | 12 | 0 |
Quality Earnings: 0JS is currently unprofitable.
Growing Profit Margin: 0JS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 0JS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 0JS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0JS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: 0JS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.